Ewing's Sarcoma family tumors (ESFT) are characterized by a translocation t(11:22) forming an aberrant transcription factor EWS-FLI1. Protein tyrosine phosphatase L1 (PTPL1) was identified as a gene upregulated by EWS-FLI1 in transfected cells by microarray. Our results show that PTPL1 is a transcriptional target of EWS-FLI1 both by chromatin immunoprecipitation and promoter activation studies. We demonstrate that PTPL1 is highly expressed in ESFT cells and patient tumors compared with normal tissues, with a trend towards higher expression in metastatic versus primary tumors. Reduction of PTPL1 protein in ESFT cells correlated with a significant reduction in both monolayer and soft-agar cell growth. In addition, these PTPL1-reduced cells were more sensitive to etoposide-induced apoptosis than the controls. We therefore report a novel transcriptional activation of a phosphatase involved in the oncogenesis of ESFT. Increasing interest in specific phosphatase inhibitors would allow PTPL1 to be evaluated as a therapeutic target in ESFT.
Introduction
Ewing's Sarcoma family of tumors (ESFT) affect patients between the ages of 3 and 40 years, with most cases occurring in the second decade; improved survival is needed (Grier et al., 2003) . ESFT are characterized by chimeric fusions between the ews gene and members of the ets family of transcription factors, usually the fli1 gene, which is not expressed in ESFT (May et al., 1993) . This fusion forms the oncogenic transcription factor EWS-FLI1. As a transcription factor, EWS-FLI1 is thought to promote and maintain tumorigenesis based on modulating key targets. Id2 (Nishimori et al., 2002) , EAT-2 ( Thompson et al., 1996) , PDGF-C (Zwerner and May, 2001 ), c-myc (Dauphinot et al., 2001) , PIM-3 (Deneen et al., 2003b) , tenascin-c (Watanabe et al., 2003) , and uridine phosphorylase (Deneen et al., 2003a) are upregulated while p57KIP2 (Dauphinot et al., 2001) , p21 (Nakatani et al., 2003) , and TGFbRII (Hahm et al., 1999) are downregulated by EWS-FLI1, either directly or indirectly. Identification of EWS-FLI1 targets can elucidate its role in ESFT oncogenesis. Based upon our previous observations in EWS-FLI1 transformed fibroblasts (Toretsky et al., 1997) and published microarray data (Khan et al., 2001; Lessnick et al., 2002; Baer et al., 2004) , we investigated the protein tyrosine phosphatase PTPL1 as a target of the EWS-FLI1 oncogene.
PTPL1 (PTP-BAS, PTP1E, PTPN13, and FAP-1) is a 270 kDa protein tyrosine phosphatase (PTP), with five PDZ (PSD95/Dlg/Z-1 homology) domains, a carboxy terminus tyrosine phosphatase domain and a FERM (band 4.1, ezrin, radixin, and moesin) domain (Banville et al., 1994; Saras et al., 1994) . PTPL1 is a nonreceptor type PTP and the FERM domain is necessary for the targeting of the enzyme to the apical face of the plasma membrane (Bompard et al., 2003) . Protein interactions with PTPL1, include the carboxy terminal of Fas (Saras et al., 1997a) a novel Zyxin-related protein ZRP-1 (Murthy et al., 1999) , and a GTPase-activating protein for Rho (PARG1) (Saras et al., 1997b) . IkBa was identified as a substrate for PTPL1 by both yeast two hybrid screen (Maekawa et al., 1999) and a substratetrapping mutant of PTPL1 (Nakai et al., 2000) . While many structural interactions of proteins with PTPL1 are reported, the functional consequences of PTPL1-induced dephosphorylation are unknown (Erdmann, 2003) .
Phosphatases can promote tumorigenesis (Gil-Henn and Elson, 2003) , but to our knowledge, have never been shown to be the direct transcriptional target of an oncogenic transcription factor. Here, we identify PTPL1 as a novel transcriptional target for the EWS-FLI1 oncogenic fusion protein. PTPL1 also appears to be necessary for maintenance of the ESFT transformed phenotype. These findings support PTPL1 as a potential therapeutic target for patients with ESFT.
Results

PTPL1 is a direct transcriptional target of EWS-FLI1
Since EWS-FLI1 is a well-characterized transcription factor, we explored whether PTPL1 is a direct or indirect transcriptional target of EWS-FLI1. The induction of PTPL1 RNA in cells transfected with EWS-FLI1 was shown by others using microarray analysis (Lessnick et al., 2002) . Our analysis of the PTPL1 promoter sequence identified multiple potential EWS-FLI1 DNA binding sites, which are characterized by a core GGAA sequence (Mao et al., 1994) . The fulllength PTPL1 promoter contains nine GGAA sequences in separate locations. In order to confirm a direct physical interaction between EWS-FLI1 and the PTPL1 promoter within the transcriptional complex, we performed chromatin immunoprecipitation studies. We selected PCR primers (inward turning arrows, Figure 1a ) to amplify the region around the first two GGAA sites since these sites showed the highest transcriptional activity in ESFT cells compared with other sites (data not shown). We used the FLI1 antibody to immunoprecipitate since FLI1 is not expressed in ESFT cells and previous chromatin immunoprecipitation assays were successful (Nishimori et al., 2002) . PCR amplification of the precipitated DNA with these primers confirmed that EWS-FLI1 protein is bound, either directly or through a multiprotien complex, to this region of the promoter (Figure 1b, upper panel) . As a control, no signal is seen in the control immunoprecipitations ( Figure 1b , middle panel). Additional controls included immunoprecipitation with anti-FLI1 followed by amplification with primers to the promoter region of hEAT, which was previously shown not to be a direct target of EWS-FLI1 (Fukuma et al., 2003) (data not shown). Immunoprecipitation by FLI1 antibody of crosslinked COS7 chromatin do not enrich the PTPL1 promoter since these cells do not have endogenous EWS-FLI1 (Figure 1b, upper panel) . When COS7 cells are transfected with EWS-FLI1 expression construct, the PTPL1 promoter is enriched upon immunoprecipitation with the FLI1 antibody (Figure 1b, upper panel) , showing an interaction between exogenously expressed EWS-FLI1 and the endogenous promoter. Control immunoprecipitation confirms the absence of any nonspecific interaction (Figure 1b , middle panel).
PTPL1 promoter is activated by EWS-FLI1
We evaluated whether EWS-FLI1 activates transcription from the PTPL1 promoter. We cloned the fulllength PTPL1 promoter and five combinatorial fragments, based upon the location of GGAA core binding sites, into the pGL3 vector upstream of a luciferase Chromatin immunoprecipitation was performed by crosslinking the DNA of TC71, TC32, A4573 (with endogenous EWS-FLI1), and COS7 cells with and without exogenous EWS-FLI1 expression (pE-F) followed by enrichment of DNA-protein complexes with anti-FLI1 antibody. A region of 521 bp from PTPL1 promoter containing the first two GGAA sites (at positions À1553 and À1762) was amplified by PCR. Control IP for TC71 was no antibody while all others was the rabbit polyclonal antibody to the PDGFRa since the FLI1 is a rabbit polyclonal antibody. Input represents the crosslinked DNA prior to immunoprecipitation. (c) ESFT cells lines TC32 (gray bars) and TC71 (black bars), which have endogenous EWS-FLI1, were transiently transfected with GL3, AY, AW, and AWm (mutant of both GGAA sites). Bars are the means of fold increase in luciferase activity over GL3 and error bars show the standard deviations (*P ¼ 0.033, **P ¼ 0.0033). (d) COS7 cells were cotransfected with and without EWS-FLI1 (black and gray bars, respectively) expression vector and GL3, AW, AWm-a (mutant of the first GGAA site), AWm-b (mutant of the second GGAA site), and AWm (mutant of both GGAA sites) constructs. EWS-FLI1 expression was confirmed by immunoblot analysis. Bars represent the means of luciferase activity and error bars are the standard deviations (*P ¼ 0.017). Transfection assays were performed in triplicate in two independent experiments reporter gene. Two different models were evaluated for activation of the PTPL1 promoter by EWS-FLI1 including: (i) ESFT cell lines with endogenous EWS-FLI1 and (ii) COS7 cells with transiently expressed EWS-FLI1. We initially tested all six promoter fragments in ESFT cell lines with endogenous EWS-FLI1. Only fragment AW, containing the two distal GGAA sites, showed a significant increase in activity over background. The follow-up experiments employed ESFT cell lines TC71 and TC32, which were transfected with AW and AY (full-length) constructs. The AY construct had a consistent two-fold increase in luciferase activity in both cell lines (Figure 1c ). The AW construct demonstrated the highest levels of activity, four-fold in TC32 cells and 12-fold in TC71 cells over background (pGL3). These findings corroborate our chromatin immunoprecipitation results. To confirm that the GGAA sites are important for promoter activity, we mutated both GGAA sites (AWm). In both TC71 and TC32 cell lines, the luciferase activity of the mutant AW fragment decreased significantly (P ¼ 0.033 and 0.0033 respectively by t-test) compared with the wild-type AW construct ( Figure 1c) .
In order to further confirm that EWS-FLI1 was responsible for the promoter activity, we used a cell line that lacks EWS-FLI1. COS7 cells cotransfected with the PTPL1 promoter reporter AW and EWS-FLI1 showed 2.2-fold increase in PTPL1 promoter activity compared with COS7 cells lacking EWS-FLI1 (Figure 1d ). When the two EWS-FLI1 binding sites present in the AW construct were mutated (AWm), the transcriptional activity is significantly reduced to 58% of the wild type ( Figure 1d , P ¼ 0.017, t-test). Mutating either of the EWS-FLI1 sites in the AW construct (AWm-a and AWm-b) independently gives intermediate promoter activities of 85 and 76% compared to wild-type AW ( Figure 1d ).
PTPL1 protein is expressed in EWS-FLI1 cell lines 4and ESFT patient tumor samples
Induction of EWS-FLI1 regulated genes that enhance oncogenesis have been sough as potential therapeutic targets in patients with ESFT. Since the PTPL1 promoter is activated by EWS-FLI1, we explored whether endogenous PTPL1 protein is present in EWS-FLI1 expressing cells, including fibroblasts stably transfected with EWS-FLI1, ESFT cell lines and ESFT patient tumor tissues. We created polyclonal murine embryonic fibroblasts (W cells) that stably express EWS-FLI1 (WA6). WA6 soft-agar colonies were expanded to create monoclonal cell lines also expressing EWS-FLI1 (A6d and A6l). Fibroblasts that lacked EWS-FLI1 (W) had low or undetectable levels of PTPL1 while EWS-FLI1 expressing cells (WA6, A6d and A6l) demonstrated induction and expression of PTPL1 (Figure 2a ). All EWS-FLI1 expressing fibroblasts produced softagar colonies while fibroblasts without EWS-FLI1 cells did not grow in soft-agar (data not shown). We therefore demonstrate that EWS-FLI1 expression correlates with the induction of PTPL1 protein, thereby supporting our hypothesis that EWS-FLI1 regulates the expression of PTPL1.
ESFT cell lines (n ¼ 8) that express endogenous EWS-FLI1 demonstrate high PTPL1 protein levels while nontumorigenic cell lines (n ¼ 3) have low PTPL1 levels ( Figure 2b ). Nontransformed W, HEK293, and COS7 cells were selected as nontumorigenic controls since the Ewing's Sarcoma cell of origin is currently unknown (de Alava and Gerald, 2000) . To establish the clinical relevance of our findings, immunohistochemistry was performed on patient tissue samples. PTPL1 antibody was optimized for immunohistochemistry using TC32 cells grown in nude mice (Figure 2c ). Biopsies from patients with ESFT were collected and placed onto a tissue multiarray that contained 41 evaluable triplicate samples (20 primary and 21 metastatic tumors). PTPL1 protein was detected in 90% of the localized tumors and 95% of the metastatic tumors (Figure 2d) . A comparison of PTPL1 levels in normal tissues, primary, and metastatic tumors showed a significant increase in staining intensity (P ¼ 0.003, Kruskal-Wallis test). Comparison of normal versus either primary or metastatic PTPL1 staining was also significant (Po0.05 and o0.001, respectively, Dunn's multiple comparisons test). The median PTPL1 staining of primary versus metastatic tumors approached statistical significance (P ¼ 0.08, Mann-Whitney test). The intensity of PTPL1 staining was scored as 0, 1 þ (renal tubules, Figure 2c 
Reducing PTPL1 decreases ESFT proliferation and colony formation
Since we show PTPL1 as a transcriptional target of EWS-FLI1, we investigated whether PTPL1 contributes to the growth and malignant phenotype of ESFT. To reduce PTPL1 levels, ESFT TC71 cells were transfected with either a plasmid expressing antisense PTPL1 (pBABE-AS), empty-vector (pBABE) or green fluorescent protein (pBABE-GFP). Clones from pBABE-AS, pBABE, and pBABE-GFP transfected cells were stably selected with puromycin. Selective pressure caused cells transfected with pBABE-AS to produce fewer colonies than empty-vector on tissue culture plastic (Figure 3a) , implying that the antisense reduction of PTPL1 impedes cell growth. Multiple colonies derived from single cells were expanded for further studies, including those with pBABE and pBABE-GFP controls. We demonstrate reduced PTPL1 levels in antisense clones compared to empty-vector and GFP transfected as well as wild type when standardized for b-tubulin levels (Figure 3b ). Densitometric analysis show antisense clones A, B, and C to have 31, 27, and 23% expression of PTPL1 compared to wild-type TC71. All six cell lines had comparable EWS-FLI1 levels. To confirm that the antisense fragment was not toxic in a nonspecific manner, two human pancreatic carcinoma and one murine osteosarcoma cell lines were transfected and colonies selected as in Figure 3a . After 3 weeks, colony counts were as follows for empty vector or antisense fragment: COLO-357 (human) 2878 and 32714, COLO-PL (human) 114714 and 7677, and K7M2 (murine) 71718 and 86710, respectively. These results do not suggest any nonspecific toxicity to account for our ESFT cell line results.
Cell growth for the PTPL1-reduced and control clones were evaluated after 24, 48 and 72 h (Figure 4a ). When the rates of growth are compared between PTPL1-reduced clones and controls, the PTPL1-reduced clones display a significant reduction in growth rate (P ¼ 0.023, t-test). When PTPL1-reduced clones and controls were plated in soft agar, the PTPL1-reduced clones (Figure 4b ) produced seven-fold fewer colonies than controls (Figure 4c ). Differences in soft-agar growth were highly significant between the PTPL1-reduced clones and the controls (Po0.0001, t-test). These data report the average of two experiments performed in triplicate.
PTPL1 reduction chemosensitizes ESFT cells
We further explored the functional implication of PTPL1 in ESFT cells by evaluating chemosensitivity in the PTPL1-reduced clones. Log phase PTPL1-reduced and control clones were treated for 6 h with etoposide, currently used in the treatment of patients with ESFT (Grier et al., 2003) . Caspase-3 activity was measured by cleavage of the substrate DEVD-AMC releasing the fluorescent AMC for fluoroscopic quantitation. Caspase-3 activity increases 2.2-fold in control cells (GFP-Y and EV-Z) but rises to 4.5-to six-fold in antisense clones (AS-A, B, C, and D) above untreated cells. Therefore, the four PTPL1-reduced clones (AS-A, B, C, and D) displayed greater sensitivity to etoposide treatment when compared to controls (GFP-Y and EV-Z) (Figure 4d ). In each case, the four PTPL1-reduced 
Discussion
The maintenance of the malignant phenotype in ESFT cells is dependent upon EWS-FLI1 (Kovar et al., 1996; Tanaka et al., 1997) . EWS-FLI1 regulates those gene products responsible for the malignant phenotype and this work supports PTPL1 as a direct transcriptional target of EWS-FLI1. Both of our model systems demonstrated that the PTPL1 promoter construct AW had significantly greater activity than the full-length promoter, suggesting the presence of regulatory domains at the 3 0 end of the promoter. The COS7 model had high background with the AW promoter fragment alone likely due to basal activation unrelated to the GGAA site or EWS-FLI1 protein. This suggests that there are additional regulatory sequences on the PTPL1 promoter. These transcription activation assay results are corroborated by chromatin immunoprecipitation. Further support that PTPL1 is an EWS-FLI1 regulated transcript comes from fibroblasts with exogenously expressed EWS-FLI1 compared to cells that lack EWS-FLI1 (Lessnick et al., 2002) . Moreover, two independent groups identified PTPL1 as a gene highly expressed in only Ewing's Sarcoma patient samples and cell lines, but not in other pediatric cancer samples and cell lines from neuroblastoma, rhabdomyosarcoma, and non-Hodgkin's lymphoma (Khan et al., 2001; Baer et al., 2004) .
It is clear that phosphatases can be positive regulators of growth and tumorigenesis through the insulin-like growth factor-I receptor (IGF-IR) and other growthfactor systems. SH-PTP2 (SYP) is found in complexes with both IGF-IR and insulin receptor substrate 1 (IRS-1) (Seely et al., 1995; Tanaka et al., 1996) and acts to increase mitogenic signaling through MAP-kinase (Xiao et al., 1994) . Additional evidence supports SH-PTP2 as important in transformation (Tanaka et al., 1996) . The receptor type PTP, PTPe is induced in Neu-transformed cells where it activates Src (Gil-Henn and Elson, 2003) . PTPe depleted cells grow much slower both in vitro and in vivo (Gil-Henn and Elson, 2003) .
Our previous studies showed that the IGF-IR is required for EWS-FLI1 transformation of fibroblasts, and that EWS-FLI1 acts to modulate IGF-IR signaling (Toretsky et al., 1997) . The expression of EWS-FLI1 qualitatively altered IRS-1 phosphorylation, resulting in basal hypophosphorylation (Toretsky et al., 1997) . PTPL1 is now an attractive candidate to explain the altered phosphorylation of IRS-1 since neither the putative phosphatase nor a link between EWS-FLI1 and IGF-IR signaling has yet been identified in ESFT. PTPL1 interacts directly with IGF mediated survival signaling through IRS-1/PI3-Kinase/Akt signaling in breast cancer cells (Bompard et al., 2002) . Additional evidence that places PTPL1 in the IGF signaling pathway demonstrates PTPL1 existing in a complex with phosphatidylinositol 4,5-biphosphate (Bompard et al., 2003) , suggesting that PTPL1 functions in close proximity with PI3-kinase, although the latter has not been shown. PTPL1 augments tumorigenicity through interactions with Fas (Ungefroren et al., 1998; Lee et al., 1999; Myc et al., 1999) and IkBa (Fan et al., 2002 (Fan et al., , 2003 . However, depending on the model system used, a significant effect of PTPL1 upon Fas is not always observed (Houghton et al., 1997; Komada et al., 1997; Uslu et al., 1997) . A recent study has shown that PTPL1 alters trafficking of Fas to the membrane (Ivanov et al., 2003) . Fas signaling is important to evaluate in ESFT since ESFT cells have been shown to express both Fas and Fas-ligand, without autologous killing (Kontny et al., 1998; Mitsiades et al., 1999) . PTPL1 or downstream targets could therefore be responsible for the lack of Fas killing in ESFT.
Our work supports adding PTPL1 to the growing list of EWS-FLI1 targets that are important for the maintenance of the tumorigenic phenotype. Here, we show that PTPL1 is an important phosphatase in ESFT tumorigenesis, and its reduction not only reduces ESFT growth but also sensitizes drug-induced caspase-3 activation suggesting apoptosis. Together this work suggests that PTPL1 plays a role in the malignant potential of ESFT and could be a therapeutic target. If validated as a clinical target in ESFT, small molecular inhibitors designed to inhibit PTPL1 might ultimately improve survival of patients with ESFT.
Materials and methods
Chemicals and cell lines
All chemicals and antibodies were purchased from Sigma and Santa Cruz Biotechnologies, respectively, except b-tubulin antibody, which was purchased from ICN Biomedicals. TransIT-TKO for transfection experiments was purchased from Mirus. ESFT cell lines were reported previously (Kontny et al., 1998) . Human pancreatic cell lines COLO-357, COLO-PL, and K7M2 were generous gifts of Dr Kim Jessup and Dr Chand Khanna, respectively.
Chromatin immunoprecipitation assay
The chromatin immunoprecipitation experiments were performed according to the manufacturer's protocol (Upstate Biotechnology) after crosslinking with 1% formaldehyde for 15 min. Anti-FLI1 antibody precipitated, no antibody or nonspecific IgG controls and the input were amplified with PCR (see Supplemental Table 1 for primer sequences).
PTPL1 promoter cloning, site-directed mutagenesis and luciferase assays
Sequence analysis of the PTPL1 promoter (Irie et al., 2001) revealed nine possible EWS-FLI1 binding sites, which have a core GGAA sequence. Using specific primers, a full-length and a partial fragment were amplified by PCR from HEK293 genomic DNA. The primers used to for cloning were (A), (W), and (Y) (see Supplemental Table 1 for sequences). Each fragment was labeled according to the primer pair used for PCR amplification, such that AY is the full-length and AW is the truncated promoter construct (from À1953 to À937). PCR products were cloned into pGL3-Enhancer vector (Promega). The first and second GGAA sites on the AW construct were mutated to TCAA and to GTCA using mutagenesis primers, respectively (see Supplemental Table 1 for sequences).
Mutations using QuickChange II XL Site-Directed Mutagenesis Kit (Stratagene) performed per manufacturers' protocol. All cloning products were sequenced.
For transient transfection assays, cells were plated in 96-well plates in 100 ml in triplicate. TransIT-TKO transfection reagent (Mirus) was used for transfecting the luciferase reporter, and b-galactosidase expression vectors. In addition, for COS7 cells, EWS/FLI1 expression vector was also cotransfected. After 24 h, cells were lysed and assayed for luciferase and b-galactosidase activity. Luciferase readings were divided by the b-galactosidase readings to standardize for transformation efficiencies. Experiments were carried out twice in triplicate.
Immunohistochemistry of tissue multiarrays
Immunohistochemistry was carried out as previously described (Uren et al., 2003) . Triplicate biopsies from each patient were included, which were confirmed to have ESFT by the presence of EWS-FLI1 using RT-PCR, and MIC2 by immunohistochemistry. Patient informed consent was obtained for laboratory studies. Tissue multiarrays were stained with antibodies against PTPL1 and scored by a trained microscopist (PAF) with extensive immunohistochemistry experience, who was blinded as for the specimen details. InStat Statistical package (GraphPad Software Inc) was used for statistical analysis.
Preparation of stable expression clones
EWS-FLI1 was cloned into pBABE-puro and retroviruses were made in BOSC cells. Mouse embryonic fibroblasts (W cells) were transfected with the virus to get stably expressing EWS-FLI1 cells (WA6). WA6 cells were grown in soft agar and single-cell colonies were selected and expanded (A6d and A6l). EWS-FLI1 and PTPL1 protein levels were determined by immunoblotting. PTPL1 (H-300) antibody from Santa Cruz Biotechnology crossreacts with mouse PTPL1. PTPL1 antisense was previously published (Freiss et al., 1998) . PCR primers were designed to amplify a 655 bp fragment from TC71 cDNA (see Supplemental Table 1 for sequences). After PCR amplification, the products were cloned into pBABEpuro. The vector was named as pBABE-AS. TC71 cells were electroporated with pBABE-AS, pBABE-GFP, and pBABE vectors and were plated on 10 cm dishes with puromycin (2 mg/ ml). Single colonies from pBABE-AS, pBABE, and pBABE-GFP transfected cells were clonally expanded and the amount of PTPL1 was determined quantitatively by immunoblot. Pancreatic and osteosarcoma control cell lines were transfected with the same antisense fragment cloned into pCI-neo (Promega) for higher expression.
Soft-agar, monolayer growth and caspase-3 assays Soft-agar assays were carried out as previously described (Toretsky et al., 1997) . Monolayer growth was assessed by triplicate plating of cells into three identical plates. Cells were quantified using 10 ml of WST-1 Reagent (Roche) according to the manufacturer's protocol after 24, 48, and 72 h. Caspase-3 was assayed as previously reported (Toretsky et al., 1999) .
Abbreviations ESFT, Ewing's Sarcoma family tumors; IGF-IR, insulin-like growth factor-I receptor; IRS-1, insulin receptor substrate 1; PTPL1, protein tyrosine phosphatase L1; PTP, protein tyrosine phosphatase.
